BCL2L11 and cancer: To the best of our knowledge, this study is the first and the largest sample size synopsis of the literature on the effect of BIM deletion polymorphism on intrinsic resistance and clinical efficacy and survival of cancer patient with kinase inhibitor targeted therapy.